Compare Natera Inc. Common Stock (NTRA) vs Patterson-UTI Energy Inc. Common Stock (PTEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Patterson-UTI Energy Inc. Common Stock — how do they compare? Natera Inc. Common Stock trades at $393.93 (market cap $57.03B), while Patterson-UTI Energy Inc. Common Stock trades at $11.6 (market cap $4.40B). The key difference: Natera Inc. Common Stock is far larger — about 13× Patterson-UTI Energy Inc. Common Stock's market cap, and Patterson-UTI Energy Inc. Common Stock pays a 3.47% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Patterson-UTI Energy Inc. Common Stock for 3 Days on average.
| NTRA | PTEN | |
|---|---|---|
Market Cap | $57.03B | $4.40B |
Volume | 1,131,157 | 9,245,690 |
Sector | Health | Energy |
52-Week High | $425.64 | $13.15 |
52-Week Low | $179.42 | $5.41 |
Typical Hold Time | 0 Days | 3 Days |
Enterprise Value | $56.18B | $5.49B |
Dividend Yield | — | 3.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Patterson-UTI Energy (PTEN) trades at $11.52, up 1.68% today, with a neutral technical signal. The stock shows strong cash flow from operations at $961.22M for 2025, but net income remains negative at -$93.64M. Recent earnings beats and an upcoming Q3 2026 report on October 29, 2026, highlight operational momentum, supported by an average of 103 drilling rigs in September 2026. Analyst consensus is bullish with a $13.38 price target, indicating a 16% upside.
The outlook is cautiously optimistic due to earnings consistency and positive analyst sentiment, but risks include persistent net losses, exposure to oil price volatility, and competitive pressures. Upside potential hinges on sustained rig demand and profitability improvements, while downside risks stem from macroeconomic headwinds affecting energy sectors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Patterson-UTI Energy Inc. Common Stock
Patterson-UTI Energy provides drilling, completion, and other oilfield services for oil and gas producers in the United States.
Read more on PTEN →
